Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
J Biol Chem ; 299(1): 102720, 2023 01.
Artículo en Inglés | MEDLINE | ID: mdl-36410440

RESUMEN

Cancer cells, including those of prostate cancer (PCa), often hijack intrinsic cell signaling to reprogram their metabolism. Part of this reprogramming includes the activation of de novo synthesis of fatty acids that not only serve as building blocks for membrane synthesis but also as energy sources for cell proliferation. However, how de novo fatty acid synthesis contributes to PCa progression is still poorly understood. Herein, by mining public datasets, we discovered that the expression of acetyl-CoA carboxylase alpha (ACACA), which encodes acetyl-CoA carboxylase 1 (ACC1), was highly expressed in human PCa. In addition, patients with high ACACA expression had a short disease-free survival time. We also reported that depletion of ACACA reduced de novo fatty acid synthesis and PI3K/AKT signaling in the human castration-resistant PCa (CRPC) cell lines DU145 and PC3. Furthermore, depletion of ACACA downregulates mitochondrial beta-oxidation, resulting in mitochondrial dysfunction, a reduction in ATP production, an imbalanced NADP+/NADPhydrogen(H) ratio, increased reactive oxygen species, and therefore apoptosis. Reduced exogenous fatty acids by depleting lipid or lowering serum supplementation exacerbated both shRNA depletion and pharmacological inhibition of ACACA-induced apoptosis in vitro. Collectively, our results suggest that inhibition of ectopic ACACA, together with suppression of exogenous fatty acid uptake, can be a novel strategy for treating currently incurable CRPC.


Asunto(s)
Acetil-CoA Carboxilasa , Ácidos Grasos , Mitocondrias , Neoplasias de la Próstata Resistentes a la Castración , Humanos , Masculino , Acetil-CoA Carboxilasa/metabolismo , Ácidos Grasos/metabolismo , Mitocondrias/genética , Mitocondrias/metabolismo , Fosfatidilinositol 3-Quinasas/genética , Neoplasias de la Próstata Resistentes a la Castración/genética , Neoplasias de la Próstata Resistentes a la Castración/metabolismo , Línea Celular Tumoral
2.
Cancer Res ; 80(11): 2150-2162, 2020 06 01.
Artículo en Inglés | MEDLINE | ID: mdl-32179514

RESUMEN

Metformin is an oral drug widely used for the treatment of type 2 diabetes mellitus. Numerous studies have demonstrated the value of metformin in cancer treatment. However, for metformin to elicit effects on cancer often requires a high dosage, and any underlying mechanism for how to improve its inhibitory effects remains unknown. Here, we found that low mRNA expression of glycerol-3-phosphate dehydrogenase 1 (GPD1) may predict a poor response to metformin treatment in 15 cancer cell lines. In vitro and in vivo, metformin treatment alone significantly suppressed cancer cell proliferation, a phenotype enhanced by GPD1 overexpression. Total cellular glycerol-3-phosphate concentration was significantly increased by the combination of GPD1 overexpression and metformin treatment, which suppressed cancer growth via inhibition of mitochondrial function. Eventually, increased reactive oxygen species and mitochondrial structural damage was observed in GPD1-overexpressing cell lines treated with metformin, which may contribute to cell death. In summary, this study demonstrates that GPD1 overexpression enhances the anticancer activity of metformin and that patients with increased GPD1 expression in tumor cells may respond better to metformin therapy. SIGNIFICANCE: GPD1 overexpression enhances the anticancer effect of metformin through synergistic inhibition of mitochondrial function, thereby providing new insight into metformin-mediated cancer therapy.


Asunto(s)
Glicerolfosfato Deshidrogenasa/metabolismo , Glicerofosfatos/metabolismo , Metformina/farmacología , Neoplasias/tratamiento farmacológico , Neoplasias/metabolismo , Células A549 , Adenosina Trifosfato/biosíntesis , Animales , Antineoplásicos/farmacología , Procesos de Crecimiento Celular/fisiología , Línea Celular Tumoral , Respiración de la Célula/fisiología , Sinergismo Farmacológico , Glicerolfosfato Deshidrogenasa/biosíntesis , Glicerolfosfato Deshidrogenasa/genética , Células HCT116 , Xenoinjertos , Humanos , Masculino , Ratones , Ratones Endogámicos BALB C , Ratones Desnudos , Mitocondrias/metabolismo , Neoplasias/genética , Neoplasias/patología , Células PC-3 , ARN Mensajero/genética , ARN Mensajero/metabolismo , Especies Reactivas de Oxígeno/metabolismo
3.
Pak J Pharm Sci ; 28(4 Suppl): 1555-7, 2015 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-26431666

RESUMEN

This paper aims to study clinical curative effect of traditional Chinese medicine combined with doxycycline in treating genital Chlamydia trachomatis (Ct) and Urea plasma urealyticum (Uu) infections. The observed subjects in this paper were 60 patients who had been randomly divided into two groups, among which the control group was treated with doxycycline and the treatment group with Chinese medicine combined with doxycycline. Results showed that the curative effect of the treatment group was much better than that of the control. So it is proved that Chinese medicine combined with doxycycline is worth promoting because it is a convenient and safe way, which does not easily produce drug-resistant strain.


Asunto(s)
Infecciones por Chlamydia/tratamiento farmacológico , Chlamydia trachomatis , Doxiciclina/uso terapéutico , Enfermedades de los Genitales Femeninos/tratamiento farmacológico , Medicina Tradicional China , Infecciones por Ureaplasma/tratamiento farmacológico , Ureaplasma urealyticum , Adulto , Femenino , Humanos , Masculino
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA